Abstract
Osteoporosis is a high-prevalence disease, particularly in developed countries, and results in high costs both to the individual and to society through associated fragility fractures. There is an urgent need for identification of novel drug targets and development of new anti-osteoporotic agents. Between 30 and 80% of osteoporotic fractures cannot be prevented despite current treatments achieving relative fracture risk reduction of up to 20%, 50%, and 70% for non-vertebral, hip and spine fractures, respectively. Traditionally, the decline in gonadal hormones has been studied as the sole hormonal determinant for the loss of bone mineral density in osteoporosis. However, recent studies have identified receptors for numerous non-gonadal hormones such as PTH, angiotensin II, leptin, adiponectin, insulin and insulin-like growth factor-1 on the osteoblast lineage cells that directly regulate bone turnover. These hormones are also involved in the pathogenesis of metabolic syndrome risk factors, particularly hypertension, type-II diabetes and obesity. By activating their respective receptors on osteoblastic lineage cells, these hormones appear to act through a common mechanism by down-regulating receptors for activation of nuclear factor kappa B ligand (RANKL) and up-regulating osteoprotegerin (OPG) with inverse responses for adiponectin. Receptors for amylin, gastric inhibitory polypeptide and ghrelin and have also been identified on the osteoblast lineage cells although the roles of these receptors in bone turnover are controversial or poorly studied. Moreover, bone turnover may be independently regulated by modulation of osteoclast-osteoblast function and bone marrow adiposity. Leptin appears to be the only hormone that is a known regulator of both bone mineralisation and bone adiposity.
Keywords: Leptin, osteoblasts, osteoclasts, osteoporosis, RANK/RANKL signalling.
Current Drug Targets
Title:Osteoporosis and its Association with Non-Gonadal Hormones Involved in Hypertension, Adiposity and Hyperglycaemia
Volume: 14 Issue: 14
Author(s): Hemant Poudyal and Lindsay Brown
Affiliation:
Keywords: Leptin, osteoblasts, osteoclasts, osteoporosis, RANK/RANKL signalling.
Abstract: Osteoporosis is a high-prevalence disease, particularly in developed countries, and results in high costs both to the individual and to society through associated fragility fractures. There is an urgent need for identification of novel drug targets and development of new anti-osteoporotic agents. Between 30 and 80% of osteoporotic fractures cannot be prevented despite current treatments achieving relative fracture risk reduction of up to 20%, 50%, and 70% for non-vertebral, hip and spine fractures, respectively. Traditionally, the decline in gonadal hormones has been studied as the sole hormonal determinant for the loss of bone mineral density in osteoporosis. However, recent studies have identified receptors for numerous non-gonadal hormones such as PTH, angiotensin II, leptin, adiponectin, insulin and insulin-like growth factor-1 on the osteoblast lineage cells that directly regulate bone turnover. These hormones are also involved in the pathogenesis of metabolic syndrome risk factors, particularly hypertension, type-II diabetes and obesity. By activating their respective receptors on osteoblastic lineage cells, these hormones appear to act through a common mechanism by down-regulating receptors for activation of nuclear factor kappa B ligand (RANKL) and up-regulating osteoprotegerin (OPG) with inverse responses for adiponectin. Receptors for amylin, gastric inhibitory polypeptide and ghrelin and have also been identified on the osteoblast lineage cells although the roles of these receptors in bone turnover are controversial or poorly studied. Moreover, bone turnover may be independently regulated by modulation of osteoclast-osteoblast function and bone marrow adiposity. Leptin appears to be the only hormone that is a known regulator of both bone mineralisation and bone adiposity.
Export Options
About this article
Cite this article as:
Poudyal Hemant and Brown Lindsay, Osteoporosis and its Association with Non-Gonadal Hormones Involved in Hypertension, Adiposity and Hyperglycaemia, Current Drug Targets 2013; 14 (14) . https://dx.doi.org/10.2174/1389450119999990001
DOI https://dx.doi.org/10.2174/1389450119999990001 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
Emerging Drug Targets and Revolutionary Therapeutic Approaches for Effective Anti-Cancer Intervention
Recent advancements in cancer research have significantly advanced our understanding of the intricate molecular mechanisms driving cancer progression, leading to the identification of new drug targets and therapeutic strategies. The elucidation of complex signaling pathways and genetic aberrations associated with tumorigenesis has provided valuable insights into potential targets for intervention. ...read more
From Models to Molecules: Integrative Strategies in Herbal Product-based Drug Discovery
The toxic effects of synthetic drugs underscore the complex equilibrium between their therapeutic efficacy and the potential hazards they pose to biological systems. Natural products, with their diverse bioactive compounds and natural synergism, can help counteract synthetic drug toxicities by offering a complementary multi-targeted approach to mitigate organ damage and ...read more
New Drug Therapy for Eye Diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Kidney CYP450 Enzymes: Biological Actions Beyond Drug Metabolism
Current Drug Metabolism Clinical Experience with the Use of Angiotensin Receptor Blockers in Patients with Cardiovascular, Cerebrovascular and Renal Diseases
Current Clinical Pharmacology Histamine in Immune Regulation: Possible Roles in Autoimmune Demyelinating Disease of the Central Nervous System
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents May Adjuvant Therapy Play A Role for the Management of Renal Cell Carcinoma? A Review of Literature and Ongoing Trials
Anti-Cancer Agents in Medicinal Chemistry Pleiotropic Effects of Rimonabant: Clinical Implications
Current Pharmaceutical Design Paradoxical Thrombotic Effects of Aspirin: Experimental Study on 1000 Animals
Cardiovascular & Hematological Disorders-Drug Targets Vitamin D and Cardiovascular Disease
Current Vascular Pharmacology Editorial (Hot Topic: Neurodegeneration: The First IBRO-Middle East Neuroscience Conference)
Current Alzheimer Research (Neuro)Transmitter Systems in Circulating Immune Cells: A Target of Immunopharmacological Interventions?
Current Medicinal Chemistry Ghrelin Receptor Ligands: Design and Synthesis of Pseudopeptides and Peptidomimetics
Current Chemical Biology Preface: Vitamin D and QT Interval in Epilepsy: More than an Association?
Current Clinical Pharmacology Relationship Between Inflammation, Insulin Resistance and Type 2 Diabetes: Cause or Effect?
Current Diabetes Reviews How to Identify Subjects with Poly-Vascular Disease?
Current Vascular Pharmacology Comparison of Clinical Outcomes Between Genders Following Antihypertensive Therapy: A Meta-Analysis
Current Medicinal Chemistry Current Concepts in the Management of Diabetic Polyneuropathy
Current Diabetes Reviews Having a Promising Efficacy on Type II Diabetes, It’s Definitely a Green Tea Time
Current Medicinal Chemistry Calcium Channel Blockers - Benefits Upon Vascular Biology in Hypertensive Patients
Cardiovascular & Hematological Agents in Medicinal Chemistry Endothelins and the Role of Endothelin Antagonists in the Management of Posttraumatic Vasospasm
Current Pharmaceutical Design Atrial Fibrillation: The Emerging Role of Inflammation and Oxidative Stress
Cardiovascular & Hematological Disorders-Drug Targets Monocyte Cyclooxygenase-2 Activity: A New Therapeutic Target for Atherosclerosis?
Current Drug Targets - Cardiovascular & Hematological Disorders